Mark-David Levin
Impact in
- Hematology top 5%
- Multiple Myeloma Research and Treatments
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research
Papers in
-
- Multiple Myeloma Research and Treatments 8
- Oncology 4
- Peptidase Inhibition and Analysis 2
- CAR-T cell therapy research 1
- Co-authors
- Ira V Gupta (1 shared paper)Marinus H. J. van Oers (1 shared paper)Vanessa C. Williams (1 shared paper)Mario Petrini (1 shared paper)Steen Lisby (1 shared paper)Fritz C. Offner (1 shared paper)Stephanie C. Manson (1 shared paper)Jennifer Lynne Phillips (1 shared paper)
- Journals
- Haematologica (4 papers)Journal of Hematology & Oncology (1 paper)Oncotarget (1 paper)Blood Advances (1 paper)HemaSphere (1 paper)
- Partner nations
- NetherlandsUnited StatesAustralia
In The Last Decade
Mark-David Levin
12 papers receiving 528 citations
Peers
Comparison fields: 5 of 40
- Hematology 375
- Genetics 123
- Oncology 221
- Pathology and Forensic Medicine 73
- Molecular Biology 251
Countries citing papers authored by Mark-David Levin
This map shows the geographic impact of Mark-David Levin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark-David Levin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark-David Levin more than expected).
Fields of papers citing papers by Mark-David Levin
This network shows the impact of papers produced by Mark-David Levin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark-David Levin. The network helps show where Mark-David Levin may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark-David Levin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 229 | |
| 2 | 2015 | 93 | |
| 3 | 2018 | 51 | |
| 4 | 2020 | 33 | |
| 5 | 2020 | 27 | |
| 6 | 2020 | 26 | |
| 7 | 2019 | 24 | |
| 8 | 2019 | 21 | |
| 9 | 2018 | 19 | |
| 10 | 2015 | 8 | |
| 11 | 2020 | 2 | |
| 12 | 2026 | 1 |
About Mark-David Levin
Mark-David Levin is a scholar working on Hematology, Oncology, Genetics, Geriatrics and Gerontology and Immunology, having authored 12 papers that have together received 534 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (8 papers), Protein Degradation and Inhibitors (5 papers), Ubiquitin and proteasome pathways (2 papers), Peptidase Inhibition and Analysis (2 papers), Chronic Lymphocytic Leukemia Research (2 papers), Frailty in Older Adults (1 paper), Health Systems, Economic Evaluations, Quality of Life (1 paper) and CAR-T cell therapy research (1 paper). The work is most often cited by research in Hematology (375 citations), Genetics (123 citations), Oncology (221 citations), Pathology and Forensic Medicine (73 citations) and Molecular Biology (251 citations). Mark-David Levin has collaborated with scholars based in Netherlands, United States and Australia. Frequent co-authors include Ira V Gupta, Marinus H. J. van Oers, Vanessa C. Williams, Mario Petrini, Steen Lisby, Fritz C. Offner, Stephanie C. Manson, Jennifer Lynne Phillips, Christian H. Geisler and Kazimierz Kuliczkowski. Their work appears in journals such as Haematologica, Journal of Hematology & Oncology, Oncotarget, Blood Advances and HemaSphere.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.